Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 47 of 1,261
  1. CN 119857078

    PARP inhibitor child preparation and preparation process thereof

    BEIGENE SUZHOU BIOTECHNOLOGY CO LTD · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  2. US 12280037

    Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof

    EVOFEM BIOSCIENCES, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  3. US 12281305

    Compounds and methods for reducing prion expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  4. US 12281083

    2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof

    PTC THERAPEUTICS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  5. US 12280159

    Therapeutic protein-based nanoparticles for treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  6. US 12280113

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  7. US 12281329

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  8. US 12280122

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Dyne Therapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  9. US 12281327

    Lymphohematopoietic engineering using CAS9 base editors

    Regents of the University of Minnesota · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  10. US 12281321

    Frataxin expression constructs having engineered promoters and methods of use thereof

    VOYAGER THERAPEUTICS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  11. US 12281310

    Use of trinucleotide repeat RNAs to treat cancer

    Northwestern University · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  12. US 12281173

    Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  13. US 12281164

    Genetically engineered dual-targeting chimeric antigen receptor and use thereof

    WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  14. US 12281140

    Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  15. US 12281105

    Contraceptive compounds and methods

    Regents of the University of Minnesota · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  16. US 12280124

    Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  17. US 12281122

    PI3K inhibitors

    Cogent Biosciences, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  18. US 12281111

    Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

    Aclaris Therapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  19. US 12281056

    Methods for making and using endoxifen

    ATOSSA THERAPEUTICS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  20. US 12280029

    Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

    INSTITUT PASTEUR DE MONTEVIDEO · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  21. US 12280055

    Combination therapies

    Mirati Therapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  22. US 12280089

    Dry powder formulation of caveolin-1 peptides and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  23. US 12280063

    Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of Alzheimer's disease

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  24. US 12281079

    Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer

    Lead Discovery Center GmbH · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.